ATE496942T1 - Von cdr2 oder cdr3 von trem-1 abgeleitete sequenzen enthaltende therapeutische peptide und deren anwendungen zur inhibierung von sepsis - Google Patents

Von cdr2 oder cdr3 von trem-1 abgeleitete sequenzen enthaltende therapeutische peptide und deren anwendungen zur inhibierung von sepsis

Info

Publication number
ATE496942T1
ATE496942T1 AT05752687T AT05752687T ATE496942T1 AT E496942 T1 ATE496942 T1 AT E496942T1 AT 05752687 T AT05752687 T AT 05752687T AT 05752687 T AT05752687 T AT 05752687T AT E496942 T1 ATE496942 T1 AT E496942T1
Authority
AT
Austria
Prior art keywords
trem
cdr2
cdr3
sequences derived
peptides containing
Prior art date
Application number
AT05752687T
Other languages
German (de)
English (en)
Inventor
Gilbert Faure
Sebastien Gibot
Paola Panina
Nadia Passini
Original Assignee
Novo Nordisk As
Univ Nancy 1 Henri Poincare
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Novo Nordisk As, Univ Nancy 1 Henri Poincare filed Critical Novo Nordisk As
Application granted granted Critical
Publication of ATE496942T1 publication Critical patent/ATE496942T1/de

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/04—Peptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof
    • A61K38/10—Peptides having 12 to 20 amino acids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/177—Receptors; Cell surface antigens; Cell surface determinants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/68—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment
    • A61K47/6801—Drug-antibody or immunoglobulin conjugates defined by the pharmacologically or therapeutically active agent
    • A61K47/6803—Drugs conjugated to an antibody or immunoglobulin, e.g. cisplatin-antibody conjugates
    • A61K47/6811—Drugs conjugated to an antibody or immunoglobulin, e.g. cisplatin-antibody conjugates the drug being a protein or peptide, e.g. transferrin or bleomycin
    • A61K47/6813—Drugs conjugated to an antibody or immunoglobulin, e.g. cisplatin-antibody conjugates the drug being a protein or peptide, e.g. transferrin or bleomycin the drug being a peptidic cytokine, e.g. an interleukin or interferon
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
    • C07K14/70503—Immunoglobulin superfamily
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K7/00—Peptides having 5 to 20 amino acids in a fully defined sequence; Derivatives thereof
    • C07K7/04—Linear peptides containing only normal peptide links
    • C07K7/08—Linear peptides containing only normal peptide links having 12 to 20 amino acids
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/5005—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells
    • G01N33/5008—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics
    • G01N33/5082—Supracellular entities, e.g. tissue, organisms
    • G01N33/5088—Supracellular entities, e.g. tissue, organisms of vertebrates
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/20—Fusion polypeptide containing a tag with affinity for a non-protein ligand
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/70—Fusion polypeptide containing domain for protein-protein interaction
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2800/00—Detection or diagnosis of diseases
    • G01N2800/06—Gastro-intestinal diseases
    • G01N2800/065—Bowel diseases, e.g. Crohn, ulcerative colitis, IBS
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2800/00—Detection or diagnosis of diseases
    • G01N2800/26—Infectious diseases, e.g. generalised sepsis

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Immunology (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Cell Biology (AREA)
  • Biomedical Technology (AREA)
  • Organic Chemistry (AREA)
  • Molecular Biology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Biochemistry (AREA)
  • Hematology (AREA)
  • Toxicology (AREA)
  • Zoology (AREA)
  • Urology & Nephrology (AREA)
  • Epidemiology (AREA)
  • Genetics & Genomics (AREA)
  • Biophysics (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Physics & Mathematics (AREA)
  • Microbiology (AREA)
  • Biotechnology (AREA)
  • Analytical Chemistry (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • General Physics & Mathematics (AREA)
  • Pathology (AREA)
  • Food Science & Technology (AREA)
  • Oncology (AREA)
  • Communicable Diseases (AREA)
  • Diabetes (AREA)
AT05752687T 2004-11-29 2005-05-20 Von cdr2 oder cdr3 von trem-1 abgeleitete sequenzen enthaltende therapeutische peptide und deren anwendungen zur inhibierung von sepsis ATE496942T1 (de)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
GBGB0426146.7A GB0426146D0 (en) 2004-11-29 2004-11-29 Therapeutic peptides and method
PCT/EP2005/052338 WO2006056492A1 (en) 2004-11-29 2005-05-20 Therapeutic peptides comprising sequences derived from cdr2 or cdr3 of trem-1 and uses thereof to inhibit sepsis

Publications (1)

Publication Number Publication Date
ATE496942T1 true ATE496942T1 (de) 2011-02-15

Family

ID=33561499

Family Applications (1)

Application Number Title Priority Date Filing Date
AT05752687T ATE496942T1 (de) 2004-11-29 2005-05-20 Von cdr2 oder cdr3 von trem-1 abgeleitete sequenzen enthaltende therapeutische peptide und deren anwendungen zur inhibierung von sepsis

Country Status (14)

Country Link
US (4) US8013116B2 (enExample)
EP (1) EP1817337B1 (enExample)
JP (3) JP4951213B2 (enExample)
CN (1) CN1817901A (enExample)
AT (1) ATE496942T1 (enExample)
BR (1) BRPI0518675A2 (enExample)
DE (1) DE602005026157D1 (enExample)
ES (1) ES2360184T3 (enExample)
GB (2) GB0426146D0 (enExample)
IL (1) IL183165A (enExample)
PL (1) PL1817337T3 (enExample)
TW (1) TWI356062B (enExample)
WO (1) WO2006056492A1 (enExample)
ZA (1) ZA200703782B (enExample)

Families Citing this family (41)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20060084082A1 (en) 1997-03-07 2006-04-20 Human Genome Sciences, Inc. 186 human secreted proteins
US8981061B2 (en) 2001-03-20 2015-03-17 Novo Nordisk A/S Receptor TREM (triggering receptor expressed on myeloid cells) and uses thereof
GB0426146D0 (en) 2004-11-29 2004-12-29 Bioxell Spa Therapeutic peptides and method
BRPI0806680A2 (pt) * 2007-01-16 2015-06-16 Wyeth Corp Tratamento, detecção e monitoramento de inflamação via trem-1
JP5583575B2 (ja) * 2007-03-28 2014-09-03 ユニベルシダード デ バルセロナ 感染症と関連炎症過程の治療のためのタンパク質生成物
GR1007327B (el) * 2007-08-08 2011-06-27 Ευαγγελος Γιαμαρελλος-Μπουρμπουλης Ο διαλυτος υποδοχεας ενεργοποιησης των μυελοκυτταρων (strem-1) ως δεικτης αποτελεσματικοτητας της θεραπειας του πεπτικου ελκους
US9925282B2 (en) 2009-01-29 2018-03-27 The General Hospital Corporation Cromolyn derivatives and related methods of imaging and treatment
US12419839B2 (en) 2009-10-09 2025-09-23 Signablok, Inc. Methods and compositions for targeted delivery of protein fragments
AU2011237851B2 (en) * 2010-04-08 2015-02-05 Inserm (Institut National De La Sante Et De La Recherche Medicale) Inhibiting peptides derived from TREM-Like Transcript 1 (TLT-1) and uses thereof
CN102517287B (zh) * 2012-01-10 2013-09-11 广西大学 抑制水牛TREM1基因表达的shRNA、慢病毒表达载体及其构建方法和应用
CN108103069B (zh) 2012-02-15 2021-08-10 诺和诺德股份有限公司 结合并阻断髓样细胞表达的触发受体-1 (trem-1)的抗体
EP3456742A1 (en) 2012-02-15 2019-03-20 Novo Nordisk A/S Antibodies that bind peptidoglycan recognition protein 1
US9550830B2 (en) 2012-02-15 2017-01-24 Novo Nordisk A/S Antibodies that bind and block triggering receptor expressed on myeloid cells-1 (TREM-1)
KR20210025132A (ko) 2012-05-11 2021-03-08 주식회사 젬백스앤카엘 항염증 활성을 갖는 펩티드 및 이를 포함하는 조성물
KR101873773B1 (ko) 2012-05-11 2018-08-02 주식회사 젬백스앤카엘 류마티즘 관절염 예방 또는 치료 조성물
WO2014010971A1 (ko) 2012-07-11 2014-01-16 주식회사 카엘젬백스 세포 투과성 펩티드, 그를 포함한 컨쥬게이트 및 그를 포함한 조성물
CA2884121C (en) * 2012-09-07 2021-10-12 Inserm (Institut National De La Sante Et De La Recherche Medicale) Inhibiting peptides derived from triggering receptor expressed on myeloid cells-1 (trem-1) trem-like transcript 1 (tlt-1) and uses thereof
KR102258864B1 (ko) 2013-04-19 2021-06-01 주식회사 젬백스앤카엘 허혈성 손상 치료 및 예방용 조성물
RU2677277C2 (ru) 2013-06-07 2019-01-16 Джемвакс Энд Каэл Ко., Лтд. Биологические маркеры, которые могут быть использованы в иммунотерапии рака
JP6495899B2 (ja) 2013-06-21 2019-04-03 ジェムバックス アンド カエル カンパニー，リミティド ホルモン分泌調節剤、及びそれを含む組成物
CA2926183C (en) 2013-10-23 2018-07-03 Gemvax & Kael Co., Ltd. Composition for treating and preventing benign prostatic hyperplasia
JP6553605B2 (ja) 2013-11-22 2019-07-31 ジェムバックス アンド カエル カンパニー，リミティド 血管新生抑制活性を有するペプチド、及びそれを含む組成物
ES2809251T3 (es) 2013-12-17 2021-03-03 Gemvax & Kael Co Ltd Composición para tratar cáncer de próstata
WO2015156649A1 (ko) 2014-04-11 2015-10-15 주식회사 젬백스앤카엘 섬유증 억제 활성을 가지는 펩티드 및 이를 포함하는 조성물
US10662223B2 (en) 2014-04-30 2020-05-26 Gemvax & Kael Co., Ltd. Composition for organ, tissue, or cell transplantation, kit, and transplantation method
DK3172232T5 (en) 2014-07-17 2024-11-18 Novo Nordisk As Site directed mutagenesis of trem-1 antibodies for decreasing viscosity
KR102413243B1 (ko) 2014-12-23 2022-06-27 주식회사 젬백스앤카엘 안질환 치료 펩티드 및 이를 포함하는 안질환 치료용 조성물
ES2799511T3 (es) 2015-02-27 2020-12-18 Gemvax & Kael Co Ltd Péptido para prevenir la pérdida de audición, y composición que lo comprende
EP3318265B1 (en) 2015-07-02 2021-08-18 Gemvax & Kael Co., Ltd. Peptide having anti-viral effect and composition containing same
US11213598B2 (en) 2015-11-12 2022-01-04 The Board Of Trustees Of The Leland Stanford Junior University Labeled probe and methods of use
EP3423493A2 (en) 2016-03-04 2019-01-09 Alector LLC Anti-trem1 antibodies and methods of use thereof
KR20180123512A (ko) 2016-04-07 2018-11-16 주식회사 젬백스앤카엘 텔로머라제 활성 증가 및 텔로미어 연장 효능을 가지는 펩티드 및 이를 포함하는 조성물
CN116889562A (zh) 2016-08-31 2023-10-17 通用医疗公司 与神经退行性疾病相关的神经炎症中的巨噬细胞/小胶质细胞
AU2019248547B2 (en) 2018-04-02 2025-07-17 Bristol-Myers Squibb Company Anti-TREM-1 antibodies and uses thereof
CA3109702A1 (en) 2018-08-13 2020-02-20 Signablok, Inc. Peptides and compositions for targeted treatment and imaging
AU2019336698A1 (en) * 2018-09-05 2021-03-25 Aztherapies, Inc. Methods of treating cytokine release syndrome
KR20210113610A (ko) 2018-12-10 2021-09-16 더 제너럴 하스피탈 코포레이션 크로몰린 에스테르 및 이의 용도
CN110734470B (zh) * 2019-11-18 2021-04-16 浙江省农业科学院 一种降血脂的蚕蛹蛋白肽hpp及其应用
US12458622B2 (en) 2020-04-06 2025-11-04 The General Hospital Corporation Methods of treatment of coronavirus-induced inflammation conditions
CN113687081A (zh) * 2021-05-19 2021-11-23 大汉生物科技(广东)有限公司 髓系细胞触发受体2在制备脓毒症相关功能产品中的应用
CN120093892B (zh) * 2025-05-12 2025-07-25 中国人民解放军陆军军医大学 Lp17在制备预防/治疗自闭症的干预药物中的应用

Family Cites Families (169)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4444887A (en) 1979-12-10 1984-04-24 Sloan-Kettering Institute Process for making human antibody producing B-lymphocytes
US4873191A (en) 1981-06-12 1989-10-10 Ohio University Genetic transformation of zygotes
US4522811A (en) 1982-07-08 1985-06-11 Syntex (U.S.A.) Inc. Serial injection of muramyldipeptides and liposomes enhances the anti-infective activity of muramyldipeptides
US4716111A (en) 1982-08-11 1987-12-29 Trustees Of Boston University Process for producing human antibodies
US4741900A (en) 1982-11-16 1988-05-03 Cytogen Corporation Antibody-metal ion complexes
US4870009A (en) 1982-11-22 1989-09-26 The Salk Institute For Biological Studies Method of obtaining gene product through the generation of transgenic animals
GB8308235D0 (en) 1983-03-25 1983-05-05 Celltech Ltd Polypeptides
US4816567A (en) 1983-04-08 1989-03-28 Genentech, Inc. Recombinant immunoglobin preparations
IT1164225B (it) 1983-05-13 1987-04-08 Anic Spa Analoghi retro-invertiti del pentapeptide potenziante la bradichina bpp5a e metodi per la loro preparazione
US4736866B1 (en) 1984-06-22 1988-04-12 Transgenic non-human mammals
US5807715A (en) 1984-08-27 1998-09-15 The Board Of Trustees Of The Leland Stanford Junior University Methods and transformed mammalian lymphocyte cells for producing functional antigen-binding protein including chimeric immunoglobulin
US4683195A (en) 1986-01-30 1987-07-28 Cetus Corporation Process for amplifying, detecting, and/or-cloning nucleic acid sequences
US4683202A (en) 1985-03-28 1987-07-28 Cetus Corporation Process for amplifying nucleic acid sequences
US4980286A (en) 1985-07-05 1990-12-25 Whitehead Institute For Biomedical Research In vivo introduction and expression of foreign genetic material in epithelial cells
US4676980A (en) 1985-09-23 1987-06-30 The United States Of America As Represented By The Secretary Of The Department Of Health And Human Services Target specific cross-linked heteroantibodies
US5225539A (en) 1986-03-27 1993-07-06 Medical Research Council Recombinant altered antibodies and methods of making altered antibodies
GB8607679D0 (en) 1986-03-27 1986-04-30 Winter G P Recombinant dna product
DE122007000007I1 (de) 1986-04-09 2007-05-16 Genzyme Corp Genetisch transformierte Tiere, die ein gewünschtes Protein in Milch absondern
US4902505A (en) 1986-07-30 1990-02-20 Alkermes Chimeric peptides for neuropeptide delivery through the blood-brain barrier
US4946778A (en) 1987-09-21 1990-08-07 Genex Corporation Single polypeptide chain binding molecules
JP2972257B2 (ja) 1990-01-24 1999-11-08 株式会社日立製作所 パケット交換機
US4987071A (en) 1986-12-03 1991-01-22 University Patents, Inc. RNA ribozyme polymerases, dephosphorylases, restriction endoribonucleases and methods
US5116742A (en) 1986-12-03 1992-05-26 University Patents, Inc. RNA ribozyme restriction endoribonucleases and methods
US5258498A (en) 1987-05-21 1993-11-02 Creative Biomolecules, Inc. Polypeptide linkers for production of biosynthetic proteins
US4904582A (en) 1987-06-11 1990-02-27 Synthetic Genetics Novel amphiphilic nucleic acid conjugates
US4873316A (en) 1987-06-23 1989-10-10 Biogen, Inc. Isolation of exogenous recombinant proteins from the milk of transgenic mammals
US5080891A (en) 1987-08-03 1992-01-14 Ddi Pharmaceuticals, Inc. Conjugates of superoxide dismutase coupled to high molecular weight polyalkylene glycols
AU4308689A (en) 1988-09-02 1990-04-02 Protein Engineering Corporation Generation and selection of recombinant varied binding proteins
US5223409A (en) 1988-09-02 1993-06-29 Protein Engineering Corp. Directed evolution of novel binding proteins
US5272057A (en) 1988-10-14 1993-12-21 Georgetown University Method of detecting a predisposition to cancer by the use of restriction fragment length polymorphism of the gene for human poly (ADP-ribose) polymerase
US5530101A (en) 1988-12-28 1996-06-25 Protein Design Labs, Inc. Humanized immunoglobulins
FR2646438B1 (fr) 1989-03-20 2007-11-02 Pasteur Institut Procede de remplacement specifique d'une copie d'un gene present dans le genome receveur par l'integration d'un gene different de celui ou se fait l'integration
US5328470A (en) 1989-03-31 1994-07-12 The Regents Of The University Of Michigan Treatment of diseases by site-specific instillation of cells or site-specific transformation of cells and kits therefor
US5459039A (en) 1989-05-12 1995-10-17 Duke University Methods for mapping genetic mutations
US5413923A (en) 1989-07-25 1995-05-09 Cell Genesys, Inc. Homologous recombination for universal donor cells and chimeric mammalian hosts
AU633958B2 (en) 1989-07-25 1993-02-11 Cell Genesys, Inc. Homologous recombination for universal donor cells and chimeric mammalian hosts
SE509359C2 (sv) 1989-08-01 1999-01-18 Cemu Bioteknik Ab Användning av stabiliserade protein- eller peptidkonjugat för framställning av ett läkemedel
US5436146A (en) 1989-09-07 1995-07-25 The Trustees Of Princeton University Helper-free stocks of recombinant adeno-associated virus vectors
ES2090297T5 (es) 1989-11-06 2005-03-01 Cell Genesys, Inc. Produccion de proteinas que utilizan recombinacion homologa.
GB8928874D0 (en) 1989-12-21 1990-02-28 Celltech Ltd Humanised antibodies
US5272071A (en) 1989-12-22 1993-12-21 Applied Research Systems Ars Holding N.V. Method for the modification of the expression characteristics of an endogenous gene of a given cell line
AU7247191A (en) 1990-01-11 1991-08-05 Molecular Affinities Corporation Production of antibodies using gene libraries
US5780225A (en) 1990-01-12 1998-07-14 Stratagene Method for generating libaries of antibody genes comprising amplification of diverse antibody DNAs and methods for using these libraries for the production of diverse antigen combining molecules
WO1991010741A1 (en) 1990-01-12 1991-07-25 Cell Genesys, Inc. Generation of xenogeneic antibodies
US5314995A (en) 1990-01-22 1994-05-24 Oncogen Therapeutic interleukin-2-antibody based fusion proteins
US5427908A (en) 1990-05-01 1995-06-27 Affymax Technologies N.V. Recombinant library screening methods
IL98764A0 (en) 1990-07-10 1992-07-15 Smithkline Beecham Corp Oxamides
GB9015198D0 (en) 1990-07-10 1990-08-29 Brien Caroline J O Binding substance
US5625126A (en) 1990-08-29 1997-04-29 Genpharm International, Inc. Transgenic non-human animals for producing heterologous antibodies
ATE158021T1 (de) 1990-08-29 1997-09-15 Genpharm Int Produktion und nützung nicht-menschliche transgentiere zur produktion heterologe antikörper
US5545806A (en) 1990-08-29 1996-08-13 Genpharm International, Inc. Ransgenic non-human animals for producing heterologous antibodies
US5814318A (en) 1990-08-29 1998-09-29 Genpharm International Inc. Transgenic non-human animals for producing heterologous antibodies
US5633425A (en) 1990-08-29 1997-05-27 Genpharm International, Inc. Transgenic non-human animals capable of producing heterologous antibodies
US5661016A (en) 1990-08-29 1997-08-26 Genpharm International Inc. Transgenic non-human animals capable of producing heterologous antibodies of various isotypes
US5698426A (en) 1990-09-28 1997-12-16 Ixsys, Incorporated Surface expression libraries of heteromeric receptors
CA2092323A1 (en) 1990-10-01 1992-04-02 George Y. Wu Targeting viruses and cells for selective internalization by cells
WO1992009968A1 (en) 1990-11-27 1992-06-11 Cray Research, Inc. VECTOR WORD SHIFT BY Vo SHIFT COUNT IN VECTOR SUPERCOMPUTER PROCESSOR
DK0564531T3 (da) 1990-12-03 1998-09-28 Genentech Inc Berigelsesfremgangsmåde for variantproteiner med ændrede bindingsegenskaber
ES2223040T3 (es) 1991-04-10 2005-02-16 The Scripps Research Institute Bibliotecas de receptor heterodimerilo que usan fagemidos.
DE69231736T2 (de) 1991-05-14 2001-10-25 The Immune Response Corp., Carlsbad Gerichtete abgabe von genen, die immunogene proteine kodieren
EP0519596B1 (en) 1991-05-17 2005-02-23 Merck & Co. Inc. A method for reducing the immunogenicity of antibody variable domains
DK0587738T3 (da) 1991-06-05 2000-12-18 Univ Connecticut Destineret levering af gener, som koder for sekretionsproteiner
EP0590067A1 (en) 1991-06-14 1994-04-06 Xoma Corporation Microbially-produced antibody fragments and their conjugates
AU2515992A (en) 1991-08-20 1993-03-16 Genpharm International, Inc. Gene targeting in animal cells using isogenic dna constructs
US5565332A (en) 1991-09-23 1996-10-15 Medical Research Council Production of chimeric antibodies - a combinatorial approach
DE69233745D1 (de) 1991-12-02 2008-10-23 Cambridge Antibody Tech Herstellung von Autoantikörpern auf Phagenoberflächen ausgehend von Antikörpersegmentbibliotheken
AU3434393A (en) 1992-01-17 1993-08-03 Regents Of The University Of Michigan, The Targeted virus
US5733743A (en) 1992-03-24 1998-03-31 Cambridge Antibody Technology Limited Methods for producing members of specific binding pairs
AU3940293A (en) 1992-04-03 1993-11-08 Alexander T. YOUNG Gene therapy using targeted viral vectors
ZA932522B (en) 1992-04-10 1993-12-20 Res Dev Foundation Immunotoxins directed against c-erbB-2(HER/neu) related surface antigens
DK0598877T3 (da) 1992-06-09 2000-02-21 Hoppe Ag Falle og dørlås
FR2694851B1 (fr) 1992-08-12 1994-12-23 Sgs Thomson Microelectronics Circuit de tirage vers un état déterminé d'une entrée de circuit intégré.
CA2141602A1 (en) 1992-08-26 1994-03-03 Philip Leder Use of the cytokine ip-10 as an anti-tumor agent
US5639641A (en) 1992-09-09 1997-06-17 Immunogen Inc. Resurfacing of rodent antibodies
KR950703640A (ko) 1992-10-09 1995-09-20 가일 케이,나우톤. 간 보존 세포(liver reserve cells)
EP0672131B1 (en) 1992-10-30 2003-12-17 The General Hospital Corporation A novel cell cycle control protein
EP1024198A3 (en) 1992-12-03 2002-05-29 Genzyme Corporation Pseudo-adenoviral vectors for the gene therapy of haemophiliae
US5547835A (en) 1993-01-07 1996-08-20 Sequenom, Inc. DNA sequencing by mass spectrometry
US5424286A (en) 1993-05-24 1995-06-13 Eng; John Exendin-3 and exendin-4 polypeptides, and pharmaceutical compositions comprising same
US5498531A (en) 1993-09-10 1996-03-12 President And Fellows Of Harvard College Intron-mediated recombinant techniques and reagents
WO1995015982A2 (en) 1993-12-08 1995-06-15 Genzyme Corporation Process for generating specific antibodies
AU1736495A (en) 1994-01-31 1995-08-15 Trustees Of Boston University Polyclonal antibody libraries
US5516637A (en) 1994-06-10 1996-05-14 Dade International Inc. Method involving display of protein binding pairs on the surface of bacterial pili and bacteriophage
DE69637481T2 (de) 1995-04-27 2009-04-09 Amgen Fremont Inc. Aus immunisierten Xenomäusen stammende menschliche Antikörper gegen IL-8
AU2466895A (en) 1995-04-28 1996-11-18 Abgenix, Inc. Human antibodies derived from immunized xenomice
GB9517780D0 (en) 1995-08-31 1995-11-01 Roslin Inst Edinburgh Biological manipulation
GB9517779D0 (en) 1995-08-31 1995-11-01 Roslin Inst Edinburgh Biological manipulation
JP2978435B2 (ja) 1996-01-24 1999-11-15 チッソ株式会社 アクリロキシプロピルシランの製造方法
JP3149958B2 (ja) 1996-08-30 2001-03-26 ノボ ノルディスク アクティーゼルスカブ Ｇｌｐ―１誘導体
US5916771A (en) 1996-10-11 1999-06-29 Abgenix, Inc. Production of a multimeric protein by cell fusion method
DE69738539T2 (de) 1996-12-03 2009-03-26 Amgen Fremont Inc. Vollkommen humane Antikörper die EGFR binden
WO1998039446A2 (en) 1997-03-07 1998-09-11 Human Genome Sciences, Inc. 70 human secreted proteins
US20030175858A1 (en) 1997-03-07 2003-09-18 Ruben Steven M. 186 human secreted proteins
US6420526B1 (en) * 1997-03-07 2002-07-16 Human Genome Sciences, Inc. 186 human secreted proteins
US20030049618A1 (en) 1997-03-07 2003-03-13 Ruben Steven M. 186 human secreted proteins
US6878687B1 (en) 1997-03-07 2005-04-12 Human Genome Sciences, Inc. Protein HMAAD57
CA2283299A1 (en) 1997-03-07 1998-09-11 Human Genome Sciences, Inc. 186 human secreted proteins
ES2172149T3 (es) 1997-04-14 2002-09-16 Micromet Ag Nuevo metodo para la produccion de receptores de antigeno anti-humano y sus usos.
US6235883B1 (en) 1997-05-05 2001-05-22 Abgenix, Inc. Human monoclonal antibodies to epidermal growth factor receptor
EP1022286A4 (en) 1997-10-07 2003-04-09 Ono Pharmaceutical Co POLYPEPTIDES, FOR ENDING CODNA AND THEIR USE
US6656906B1 (en) 1998-05-20 2003-12-02 Trimeris, Inc. Hybrid polypeptides with enhanced pharmacokinetic properties
WO2000000610A2 (en) 1998-06-26 2000-01-06 Incyte Pharmaceuticals, Inc. Human signal peptide-containing proteins
US20030211510A1 (en) 1999-06-30 2003-11-13 Corixa Corporation Compositions and methods for the therapy and diagnosis of lung cancer
US20030170255A1 (en) 1999-06-30 2003-09-11 Corixa Corporation Compositions and methods for the therapy and diagnosis of lung cancer
US20020172952A1 (en) 1999-06-30 2002-11-21 Corixa Corporation Compositions and methods for the therapy and diagnosis of lung cancer
US20020197669A1 (en) 2000-12-13 2002-12-26 Bangur Chaitanya S. Compositions and methods for the therapy and diagnosis of lung cancer
US6509448B2 (en) 1999-06-30 2003-01-21 Corixa Corporation Compositions and methods for the therapy and diagnosis of lung cancer
US6858204B2 (en) 1999-06-30 2005-02-22 Corxia Corporation Compositions and methods for the therapy and diagnosis of lung cancer
US6504010B1 (en) 1999-06-30 2003-01-07 Corixa Corporation Compositions and methods for the therapy and diagnosis of lung cancer
WO2001053312A1 (en) 1999-12-23 2001-07-26 Hyseq, Inc. Novel nucleic acids and polypeptides
ES2270893T3 (es) 1999-12-24 2007-04-16 Genentech, Inc. Procedimiento y composiciones para prolongar la vida media de compuestos bioactivos.
AU2001259432B2 (en) 2000-05-03 2005-04-21 Amgen Inc. Modified peptides, comprising an FC domain, as therapeutic agents
AU2001274888A1 (en) 2000-05-19 2001-12-03 Human Genome Sciences, Inc. Nucleic acids, proteins, and antibodies
JP2004509079A (ja) 2000-08-02 2004-03-25 セラテクノロジーズ・インコーポレーテッド 効力が増大した修飾生体ペプチド
US20030134283A1 (en) 2000-10-03 2003-07-17 Peterson David P. Genes regulated in dendritic cell differentiation
EP1351702B1 (en) * 2000-12-08 2015-03-04 Bioprovar Corporation Trem-1 splice variant for use in modifying immune responses
US8231878B2 (en) 2001-03-20 2012-07-31 Cosmo Research & Development S.P.A. Receptor trem (triggering receptor expressed on myeloid cells) and uses thereof
CA2342376C (en) * 2001-03-20 2013-11-12 Marco Colonna A receptor trem (triggering receptor expressed on myeloid cells) and uses thereof
WO2003011213A2 (en) 2001-07-30 2003-02-13 Eli Lilly And Company Method for treating diabetes and obesity
AU2002330039A1 (en) 2001-09-17 2003-04-01 Eos Biotechnology, Inc. Methods of diagnosis of cancer compositions and methods of screening for modulators of cancer
EP2316485A1 (en) 2001-10-12 2011-05-04 Schering Corporation Use of bispecific antibodies to regulate immune responses
WO2003049684A2 (en) 2001-12-07 2003-06-19 Centocor, Inc. Pseudo-antibody constructs
EP2277889B1 (en) 2001-12-21 2014-07-09 Human Genome Sciences, Inc. Fusion proteins of albumin and interferon beta
EP1329227A1 (en) 2002-01-22 2003-07-23 Deutsches Krebsforschungszentrum Stiftung des öffentlichen Rechts Diagnostic conjugate useful for intercellular imaging and for differentiating between tumor- and non-tumor cells
US20060263770A1 (en) 2002-03-22 2006-11-23 Marco Colonna Novel receptor trem (triggering receptor expressed on myeloid cells) and uses thereof
US20030191056A1 (en) 2002-04-04 2003-10-09 Kenneth Walker Use of transthyretin peptide/protein fusions to increase the serum half-life of pharmacologically active peptides/proteins
AU2003265787A1 (en) 2002-08-29 2004-03-19 Five Prime Therapeutics, Inc. Methods of use for novel human polypeptides encoded by polynucleotides
US7067488B2 (en) 2002-09-25 2006-06-27 Theratechnologies Inc. Modified GLP-1 peptides with increased biological potency
GB0305478D0 (en) * 2003-03-10 2003-04-16 Bioxell Spa Diagnostic and prognostic compounds and method
US20050255114A1 (en) 2003-04-07 2005-11-17 Nuvelo, Inc. Methods and diagnosis for the treatment of preeclampsia
DE10316701A1 (de) 2003-04-09 2004-11-04 Hinzmann, Bernd, Dr. Humane Nukleinsäuresequenzen aus Bronchialkarzinomen
US20070083333A1 (en) 2003-11-17 2007-04-12 Vitiello Maria A Modeling of systemic inflammatory response to infection
GB0401730D0 (en) 2004-01-27 2004-03-03 Bioxell Spa Diagnosis method
JP2007531715A (ja) 2004-03-17 2007-11-08 イーライ リリー アンド カンパニー グリコール結合ｆｇｆ−２１化合物
EP2194064A1 (en) 2004-05-13 2010-06-09 Eli Lilly & Company FGF-21 fusion proteins
EP1789443A1 (en) 2004-09-02 2007-05-30 Eli Lilly And Company Muteins of fibroblast growth factor 21
JP4809352B2 (ja) 2004-09-02 2011-11-09 イーライ リリー アンド カンパニー 線維芽細胞成長因子２１の突然変異タンパク質
NZ543660A (en) 2004-11-29 2008-01-31 Bioxell Spa Therapeutic peptides and method
GB0426146D0 (en) 2004-11-29 2004-12-29 Bioxell Spa Therapeutic peptides and method
EP1831371A2 (en) 2004-12-14 2007-09-12 Eli Lilly And Company Muteins of fibroblast growth factor 21
EP1846019A2 (en) 2005-01-21 2007-10-24 Eli Lilly And Company Method for treating cardiovascular disease
TWI362392B (en) 2005-03-18 2012-04-21 Novo Nordisk As Acylated glp-1 compounds
US20070099209A1 (en) 2005-06-13 2007-05-03 The Regents Of The University Of Michigan Compositions and methods for treating and diagnosing cancer
MX363905B (es) 2006-06-12 2019-04-08 Aptevo Res & Development Llc Proteinas de union multivalentes monocatenarias con funcion efectora.
BRPI0806680A2 (pt) 2007-01-16 2015-06-16 Wyeth Corp Tratamento, detecção e monitoramento de inflamação via trem-1
CN107501407B (zh) 2007-03-30 2022-03-18 Ambrx公司 经修饰fgf-21多肽和其用途
EP2069401A4 (en) 2007-07-31 2011-02-23 Medimmune Llc MULTISPECIENT EPITOP BINDING PROTEINS AND THEIR USE
JP2010535781A (ja) 2007-08-03 2010-11-25 イーライ リリー アンド カンパニー 肥満に対する処置
CN101842109B (zh) 2007-09-05 2014-01-29 诺沃-诺迪斯克有限公司 用a-b-c-d-衍生的肽和它们的治疗用途
CN103543094B (zh) 2007-12-19 2017-06-09 神谷来克斯公司 单分子检测用扫描分析器和使用方法
JP2011513753A (ja) 2008-03-05 2011-04-28 シンギュレックス・インコーポレイテッド 分子の高感度検出の方法および組成物
US8697370B2 (en) 2008-05-23 2014-04-15 Pronota N.V. Biomarker for diagnosis, prediction and/or prognosis of sepsis and uses thereof
MX2010014574A (es) 2008-07-08 2011-04-27 Abbott Lab Inmunoglobulinas de dominio variable dual para prostaglandina e2 y usos de las mismas.
CN103773843A (zh) 2008-08-25 2014-05-07 詹森生物科技公司 用于溃疡性结肠炎和相关疾病的抗tnf治疗的生物标记物
JP5878757B2 (ja) 2008-10-10 2016-03-08 アムジエン・インコーポレーテツド Ｆｇｆ２１変異体およびその使用
WO2010065439A1 (en) 2008-12-05 2010-06-10 Eli Lilly And Company Variants of fibroblast growth factor 21
MX2011007544A (es) 2009-01-23 2011-08-12 Novo Nordisk As Derivados de factor de crecimiento de fibroblastos 21 (fgf21) con ligante de albumina a-b-c-d-e- y su uso.
WO2010132370A2 (en) 2009-05-11 2010-11-18 Government Of The U.S.A., As Represented By The Secretary, Department Of Health And Human Services Soluble tlt-1 for the treatment and diagnosis of sepsis
JP2012529463A (ja) 2009-06-11 2012-11-22 ノヴォ ノルディスク アー／エス ２型糖尿病を治療するための、ｇｌｐ−１とｆｇｆ２１との組合せ
AU2010270979B2 (en) 2009-06-22 2015-04-23 Medimmune, Llc Engineered Fc regions for site-specific conjugation
US9493578B2 (en) 2009-09-02 2016-11-15 Xencor, Inc. Compositions and methods for simultaneous bivalent and monovalent co-engagement of antigens
WO2011047097A2 (en) 2009-10-13 2011-04-21 Sigalov Alexander B Inhibition of trem receptor signaling with peptide variants
EP3778917A3 (en) 2009-12-04 2021-06-09 F. Hoffmann-La Roche AG Multispecific antibodies, antibody analogs, compositions, and methods
WO2011091078A2 (en) 2010-01-19 2011-07-28 Xencor, Inc. Antibody fc variants with enhanced complement activity
KR20130098161A (ko) 2010-04-30 2013-09-04 알렉시온 파마슈티칼스, 인코포레이티드 인간에서 감소된 면역원성을 갖는 항체
EP2638066A4 (en) 2010-11-09 2015-06-03 Medimmune Llc ANTIBODY EQUIPMENT FOR HOMOGENEOUS CONJUGATION
UY33826A (es) 2010-12-22 2012-07-31 Abbott Lab Proteínas de unión con dominios trivariables y sus usos
EP2654792A4 (en) 2010-12-22 2016-05-11 Abbvie Inc HALF IMMUNOGLOBULIN BINDING PROTEINS AND USES THEREOF
WO2012109624A2 (en) 2011-02-11 2012-08-16 Zyngenia, Inc. Monovalent and multivalent multispecific complexes and uses thereof

Also Published As

Publication number Publication date
WO2006056492A1 (en) 2006-06-01
EP1817337A1 (en) 2007-08-15
ES2360184T3 (es) 2011-06-01
US20200254058A1 (en) 2020-08-13
DE602005026157D1 (de) 2011-03-10
US8013116B2 (en) 2011-09-06
IL183165A0 (en) 2007-09-20
IL183165A (en) 2014-07-31
GB2433936A (en) 2007-07-11
TWI356062B (en) 2012-01-11
US20090253632A1 (en) 2009-10-08
US20160193288A1 (en) 2016-07-07
GB0426146D0 (en) 2004-12-29
US9273111B2 (en) 2016-03-01
TW200616657A (en) 2006-06-01
JP4951213B2 (ja) 2012-06-13
US20120015867A1 (en) 2012-01-19
EP1817337B1 (en) 2011-01-26
BRPI0518675A2 (pt) 2008-12-02
JP5599382B2 (ja) 2014-10-01
GB2433936B (en) 2010-06-23
ZA200703782B (en) 2010-07-28
US10603357B2 (en) 2020-03-31
JP2012082206A (ja) 2012-04-26
JP2015006180A (ja) 2015-01-15
CN1817901A (zh) 2006-08-16
GB0709406D0 (en) 2007-06-27
JP2006149365A (ja) 2006-06-15
PL1817337T3 (pl) 2011-10-31

Similar Documents

Publication Publication Date Title
ATE496942T1 (de) Von cdr2 oder cdr3 von trem-1 abgeleitete sequenzen enthaltende therapeutische peptide und deren anwendungen zur inhibierung von sepsis
EA201070812A1 (ru) Лечение и профилактика амилоидоза
WO2009103105A3 (en) Mimotopes of alpha-synuclein and vaccines thereof for the treatment of neurodegenerative disorders
EA200801842A1 (ru) Антитела против бета-амилоидного пептида
EA200970694A1 (ru) ПЭГИЛИРОВАННЫЕ Fab-ФРАГМЕНТЫ АНТИТЕЛ К ПЕПТИДУ Aβ
GEP20115324B (en) Tweak binding antibodies
CY1111225T1 (el) Νεα πεπτιδια ως αναστολεις πρωτεασης νs3-σερινης ιου ηπατiτιδας c
DK1549333T3 (da) Compstatinanaloge med forbedret aktivitet
RU2010119521A (ru) Антитела, связывающие il-4 и/или il-13, и их применение
TW200716677A (en) Human monoclonal antibodies that bind to very late antigen-1 for the treatment of inflammation and other disorders
RU2016146198A (ru) Терапевтические dll4-связывающие белки
DE602005021970D1 (de) Verwendung von peptidverbindungen zur behandlung von schmerzen durch knochenkrebs, chemotherapie- und nucleosid-bedingten schmerzen
RU2011104709A (ru) Фармацевтическая композиция для лечения и предупреждения рака
DK1117682T3 (da) Chi-conotoksin-peptider som inhibitorer af neuronale amintransportere
TW200716132A (en) Novel chemical compounds
ATE358136T1 (de) Prionen-bindende peptidsequenzen
ATE540971T1 (de) Proteinkinase-c-inhibitoren zur prävention von insulinresistenz und typ-2-diabetes
PE20080909A1 (es) Anticuerpo monoclonal contra nectina-2
TW200716579A (en) Novel chemical compounds
DE602007006493D1 (de) Peptide mit proliferationshemmender wirkung
WO2007066018A3 (fr) Peptides qui peuvent se lier a la proteine nef et leurs applications pharmaceutiques
ATE485831T1 (de) Behandlung von neurodegeneration
EA201200111A1 (ru) Новое применение ингибиторов глутаминилциклазы
UA96917C2 (ru) Антитела, направленные против пептида бета-амилоида, и способы их применения
ATE465175T1 (de) Neuer proteinkomplex und anwendungen davon

Legal Events

Date Code Title Description
RER Ceased as to paragraph 5 lit. 3 law introducing patent treaties